アダプティミューン・セラピューティクスは、がん細胞治療に取り組んでいるにもかかわらず、アナリストの意見が分かれ、格下げに直面しています。 Adaptimmune Therapeutics faces mixed analyst views and a downgrade, despite working on cancer cell therapies.

Adaptimmune Therapeutics (NASDAQ: ADAP) は,平均的な"Hold"の推奨値と12ヶ月の目標価格1.35ドルの分析家の意見が異なっている. Adaptimmune Therapeutics (NASDAQ: ADAP) faces mixed analyst views, with an average "Hold" recommendation and a 12-month price target of $1.35. 会社は最近38.91%の純利益率と163.73%の資本利回りを含む負の財務指標を報告した. The company recently reported negative financial metrics, including a 38.91% net margin and 163.73% return on equity. 三吉はその評価を"中性"に格下げし,目標価格を0.5ドルに下げた. Mizuho downgraded its rating to "neutral" with a lower target price of $0.50. Adaptimmuneは米国と英国でがん患者向けの細胞治療の開発に重点を置く. Adaptimmune focuses on developing cell therapies for cancer patients in the US and UK, with several clinical trials in progress.